Med Plus SRL (Med Plus Ltd.)

Bucharest 061118

0 studies enrolling now · 2 studies all time

What they study most

Cardiovascular Disease

Studies at this site

• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early